Status:
COMPLETED
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Immune Thrombocytopenic Purpura
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- ≥18 years old, diagnosed with persistent or chronic ITP
Exclusion
- Secondary immune thrombocytopenia
- Drug induced thrombocytopenia
Key Trial Info
Start Date :
November 17 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 22 2018
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT02273960
Start Date
November 17 2014
End Date
January 22 2018
Last Update
July 16 2019
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ. Of Southern Calif. /Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
2
Georgetown University Medical Center
Washington D.C., District of Columbia, United States, 20007
3
Emory University
Atlanta, Georgia, United States, 30322
4
Columbus Regional Research Institute
Columbus, Georgia, United States, 31904